title: Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment.
abstract: OBJECTIVE
  This study aimed to analyze survival, clinical responses, compliance, and adverse effects in locally advanced head and neck cancer (LAHNC) patients treated with split-dose cisplatin-based concurrent chemoradiation therapy (SD-CCRT) or cetuximab with concurrent radiation therapy (BioRT).
  
  
  METHODS
  We retrospectively evaluated 170 LAHNC patients diagnosed between January 1, 2009, and July 31, 2012: 116 received CCRT and 54 received BioRT.
  
  
  RESULTS
  Complete response rates were similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807), and locoregional relapse rates were 18.1% and 13.0%, respectively (P = 0.400). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group, respectively (P = 0.647). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group, respectively (P = 0.879). Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group. Mucositis frequency was similar.
  
  
  CONCLUSIONS
  Primary SD-CCRT and BioRT both showed good clinical response and survival. Hematologic toxicities were more frequent, but tolerable, in the SD-CCRT group. Both groups showed good compliance.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Cardinal Tien Hospital, No. 362, Zhongzheng Road, New Taipei City 231, Taiwan.
authors.forename: Ming-Hung
authors.initials: MH
authors.lastname: Hu
authors.affiliation: Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Cancer Center, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors.forename: Ling-Wei
authors.initials: LW
authors.lastname: Wang
authors.affiliation: Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Show Chwan Memorial Hospital, No. 542, Section 1, Zhongshan Road, Changhua City, Changhua County 500, Taiwan.
authors.forename: Hsueh-Ju
authors.initials: HJ
authors.lastname: Lu
authors.affiliation: Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors.forename: Pen-Yuan
authors.initials: PY
authors.lastname: Chu
authors.affiliation: Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors.forename: Shyh-Kuan
authors.initials: SK
authors.lastname: Tai
authors.affiliation: Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
authors.forename: Tsung-Lun
authors.initials: TL
authors.lastname: Lee
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan.
authors.forename: Ming-Huang
authors.initials: MH
authors.lastname: Chen
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Institute of Clinical Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan.
authors.forename: Muh-Hwa
authors.initials: MH
authors.lastname: Yang
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan.
authors.forename: Peter Mu-Hsin
authors.initials: PM
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology / Q000401:mortality; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D000068818:Cetuximab; D002945:Cisplatin
references.citation: Radiology. 1992 Jan;182(1):273-5
references.pmid: 1727295
references.citation: J Clin Oncol. 2003 Jan 15;21(2):320-6
references.pmid: 12525525
references.citation: Am J Roentgenol Radium Ther Nucl Med. 1969 Mar;105(3):555-65
references.pmid: 5775014
references.citation: N Engl J Med. 2007 Oct 25;357(17):1705-15
references.pmid: 17960013
references.citation: Lancet Oncol. 2010 Jan;11(1):21-8
references.pmid: 19897418
references.citation: J Clin Oncol. 2013 Mar 1;31(7):845-52
references.pmid: 23182993
references.citation: N Engl J Med. 2003 Nov 27;349(22):2091-8
references.pmid: 14645636
references.citation: J Clin Oncol. 2013 Mar 1;31(7):853-9
references.pmid: 23341517
references.citation: J Natl Cancer Inst. 1996 Sep 4;88(17):1193-203
references.pmid: 8780628
references.citation: J Clin Oncol. 2000 Apr;18(8):1652-61
references.pmid: 10764425
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Lancet Oncol. 2013 Mar;14(3):257-64
references.pmid: 23414589
references.citation: Biochem Pharmacol. 1982 Sep 15;31(18):2929-35
references.pmid: 6215922
references.citation: Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):451-4
references.pmid: 3343152
references.citation: Int J Radiat Oncol Biol Phys. 1981 Nov;7(11):1507-12
references.pmid: 7333899
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2856-64
references.pmid: 15254053
references.citation: Semin Oncol. 1992 Jun;19(3 Suppl 9):53-8
references.pmid: 1641658
references.citation: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references.pmid: 12903007
references.citation: Acta Radiol Oncol. 1985 Jul-Aug;24(4):321-5
references.pmid: 2994388
references.citation: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5936-43
references.pmid: 14676118
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544